# US 2017/0281627 A1 · Toll like receptor modulator compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281627 A1
- Document ID: US20170281627A1
- Status: Published application
- Kind: A1
- Application number: 15/496,283
- Filed: 2017-04-25
- Published: 2017-10-05
- Earliest claimed: 2015-03-04
- Assignees: Gilead Sciences, Inc.
- Applicants: Gilead Sciences, Inc.
- Inventors: Evangelos Aktoudianakis; Gregory Chin; Richard L. Mackman; Samuel E. Metobo; Michael R. Mish; Hyung-Jung Pyun; Jeff Zablocki
- Web page: https://patentgrep.com/patent/US20170281627A1

## CPC

- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61P 31/18: for HIV
- A61P 31/20: for DNA viruses
- A61P 35/00: Antineoplastic agents
- C07C 57/145: Maleic acid
- C07C 57/15: Fumaric acid
- C07C 59/255: Tartaric acid
- C07D 239/84: Nitrogen atoms
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 471/04: Ortho-condensed systems
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present disclosure relates generally to toll like receptor modulator compounds, such as diamino pyrido[3,2 D] pyrimidine compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR-8), and methods of making and using them.

## Claims

### Claim at position 1

1-102. (canceled)

### Claim 103

A method of treating a hepatitis B viral infection, comprising administering to an individual in need thereof a therapeutically effective amount of a compound which is
or a pharmaceutically acceptable salt thereof.

### Claim 104 (depends on 103)

The method of claim 103, further comprising administering one or more additional therapeutic agents.

### Claim 105 (depends on 103)

The method of claim 103, further comprising administering tenofovir alafenamide, tenofovir alafenamide fumarate, or tenofovir alafenamide hemifumarate.

### Claim 106

A method of treating a hepatitis B viral infection, comprising administering to an individual in need thereof a therapeutically effective amount of a compound which is

### Claim 107 (depends on 106)

The method of claim 106, further comprising administering one or more additional therapeutic agents.

### Claim 108 (depends on 106)

The method of claim 106, further comprising administering tenofovir alafenamide, tenofovir alafenamide fumarate, or tenofovir alafenamide hemifumarate.

### Claim 109

A method of treating a hepatitis B viral infection, comprising administering to an individual in need thereof a therapeutically effective amount of a compound which is
or a pharmaceutically acceptable salt thereof.

### Claim 110 (depends on 109)

The method of claim 109, further comprising administering one or more additional therapeutic agents.

### Claim 111 (depends on 109)

The method of claim 109, further comprising administering tenofovir alafenamide, tenofovir alafenamide fumarate, or tenofovir alafenamide hemifumarate.

### Claim 112

A method of treating a hepatitis B viral infection, comprising administering to an individual in need thereof a therapeutically effective amount of a compound which is

### Claim 113 (depends on 112)

The method of claim 112, further comprising administering one or more additional therapeutic agents.

### Claim 114 (depends on 112)

The method of claim 112, further comprising administering tenofovir alafenamide, tenofovir alafenamide fumarate, or tenofovir alafenamide hemifumarate.
